EG 427 is the worldwide leader in non-replicating HSV-1 (nrHSV-1) vector technology in neurology, with an Investigational New Drug (IND) application for its lead product cleared by the FDA cleared in June 2024. The product, EG110A, addresses multiple severe bladder diseases, such as neurogenic bladder (NDO) and overactive bladder (OAB), and has the potential to be a major improvement over existing therapies, resulting in better care for patients and lower costs for healthcare systems. The company’s unique HERMES platform delivers pinpoint neurotherapeutics to treat prevalent diseases of the peripheral and central nervous system. Its vectors can achieve focal transduction in specific regions and selective expression of transgenes in targeted subsets of neurons thanks to the control of sophisticated regulatory elements. With demonstrated clinical safety and possible repeated dosing, the large payload capacity of our vectors allows for versatile DNA delivery for smarter genetic medicine.